Summaries of health policy coverage from major news organizations
First-Line Antiretroviral Drug Triomune Registered in South Africa
Cipla Medpro on Monday announced that its first-line, combination antiretroviral drug Triomune has been registered in South Africa, Reuters South Africa reports (Reuters South Africa, 4/24). According to iafrica.com, Triomune is composed of lamivudine, nevirapine and stavudine, all of which are part of the first-line treatment regimen recommended by the Department of Health in South Africa, the South African HIV Clinicians Society, the World Health Organization and other groups. People using Triomune have increased immunity, decreased viral loads and fewer opportunistic infections and have been shown to gain weight, iafrica.com reports. The drug is thought to have lower costs associated with storage, production, dispensing and transport, which likely will increase patients' access to it in South Africa. "Triomune is indeed a breakthrough and represents Cipla Medpro's commitment to making life-saving medicines accessible and affordable to the broader population," Trevor Edwards, CEO of Enaleni Pharmaceuticals, said (iafrica.com, 4/24).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.